2 results
Approved WMOPending
To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging Progression-Free Survival (PFS) in advanced ALK-positive NSCLC participants who are treatment naive.
Approved WMOCompleted
To compare the clinical and cost-effectiveness of an anterior colporraphy repair with a cystocele repair with the use of the non-absorbable synthetic Avaulta® mesh.